Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "Research"

2650 News Found

FDA nod to first treatment for rare genetic brain disorder
Drug Approval | March 12, 2026

FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature


EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients
Clinical Trials | March 12, 2026

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation


Alcon launches Hydrus Microstent in India to transform glaucoma care
News | March 11, 2026

Alcon launches Hydrus Microstent in India to transform glaucoma care

The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes


Cirena licenses breakthrough RNA synthesis technology from CU Boulder
Biotech | March 11, 2026

Cirena licenses breakthrough RNA synthesis technology from CU Boulder

The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands


UK pushes space-made medicines from orbit to patients with new support package
R&D | March 10, 2026

UK pushes space-made medicines from orbit to patients with new support package

The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen